Literature DB >> 11571981

Characteristics of multicentric hepatocellular carcinomas: comparison with intrahepatic metastasis.

M Shimada1, T Hamatsu, Y Yamashita, T Rikimaru, K Taguchi, T Utsunomiya, K Shirabe, K Sugimachi.   

Abstract

Characteristics of multicentric hepatocellular carcinomas (HCCs) remain obscure. We therefore aimed to clarify them and compare them with HCC with intrahepatic metastases. A series of 118 patients who had definite hepatitis C viral status and multinodular HCC were divided into two groups: a multicentric occurrence (MO) group (n = 38), with multicentric HCCs; and an intrahepatic metastasis (IM) group (n = 80), with HCC having intrahepatic metastases. Clinicopathologic variables, including the patient's survival and disease-free survival rates, were compared between the MO and IM groups. Univariate analysis revealed the presence of esophageal varices, the presence of hepatitis C virus infection, a platelet count of less than 10 x 10(4)/microliter, hepaplastin test, gamma-globulin, the histologically active hepatitis, tumor size, des-gamma-carboxy prothrombin > 0.1 AU/ml, positive portal vein invasion, and histologic grade as discriminating factors. The MO score to differentiate multicentric HCCs from intrahepatic metastatic HCCs was determined using the following four independent factors selected by a stepwise regression analysis: the presence of hepatitis C virus infection, a platelet count of less than 10 x 10(4)/microliter, tumor size, and histologic grade. The sensitivity and specificity of the MO scores using those factors were 84% and 70%, respectively, when the cutoff value was 0.4. The disease-free survival rate in the MO group was similar to that in the IM group, whereas the survival rate in the MO group was significantly better than that in the IM group. The multivariate analysis revealed the multicentric occurrence of HCC as one of the independent prognostic factors. Clinicopathologic factors differentiating multicentric HCCs from intrahepatic metastatic HCCs were the presence of hepatitis C virus infection, a platelet count of less than 10 x 10(4)/microliter, small tumor size, and low histologic grade.

Entities:  

Mesh:

Year:  2001        PMID: 11571981     DOI: 10.1007/s00268-001-0068-6

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  18 in total

1.  Long-term outcome of laparoscopic ablation therapies for unresectable hepatocellular carcinoma: a single European center experience of 426 patients.

Authors:  Roberto Santambrogio; Matteo Barabino; Savino Bruno; Mara Costa; Andrea Pisani Ceretti; Maria Rachele Angiolini; Massimo Zuin; Franca Meloni; Enrico Opocher
Journal:  Surg Endosc       Date:  2015-08-15       Impact factor: 4.584

2.  Molecular alterations in the carcinogenesis and progression of hepatocellular carcinoma: Tumor factors and background liver factors.

Authors:  Yoshikuni Inokawa; Kenichi Inaoka; Fuminori Sonohara; Masamichi Hayashi; Mitsuro Kanda; Shuji Nomoto
Journal:  Oncol Lett       Date:  2016-09-15       Impact factor: 2.967

3.  Significance of anatomic resection for early and advanced hepatocellular carcinoma.

Authors:  Yoji Kishi; Akio Saiura; Junji Yamamoto; Rintaro Koga; Makoto Seki; Ryo Morimura; Ryuji Yoshioka; Norihiro Kokudo; Toshiharu Yamaguchi
Journal:  Langenbecks Arch Surg       Date:  2011-09-09       Impact factor: 3.445

4.  Multicentric occurrence of hepatocellular carcinoma with nonalcoholic steatohepatitis.

Authors:  Hirokazu Kawai; Minoru Nomoto; Takeshi Suda; Kenya Kamimura; Atsunori Tsuchiya; Yasushi Tamura; Masahiko Yano; Masaaki Takamura; Masato Igarashi; Toshifumi Wakai; Satoshi Yamagiwa; Yasunobu Matsuda; Shogo Ohkoshi; Isao Kurosaki; Yoshio Shirai; Masahiko Okada; Yutaka Aoyagi
Journal:  World J Hepatol       Date:  2011-01-27

Review 5.  Molecular profiling of hepatocellular carcinomas by cDNA microarray.

Authors:  Lian-Hai Zhang; Jia-Fu Ji
Journal:  World J Gastroenterol       Date:  2005-01-28       Impact factor: 5.742

6.  Simultaneous microwave coagulo-necrotic therapy (MCN) and laparoscopic splenectomy for the treatment of hepatocellular carcinoma with cirrhotic hypersplenism.

Authors:  Tomoki Ryu; Yuko Takami; Norifumi Tsutsumi; Masaki Tateishi; Kazuhiro Mikagi; Yoshiyuki Wada; Hideki Saitsu
Journal:  Surg Today       Date:  2016-08-30       Impact factor: 2.549

7.  Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma.

Authors:  Jiyeon Hyeon; Soomin Ahn; Jae Jun Lee; Dae Hyun Song; Cheol-Keun Park
Journal:  Dig Dis Sci       Date:  2013-03-02       Impact factor: 3.199

8.  ATAD2 as a Poor Prognostic Marker for Hepatocellular Carcinoma after Curative Resection.

Authors:  Hye Won Hwang; Sang Yun Ha; Heejin Bang; Cheol-Keun Park
Journal:  Cancer Res Treat       Date:  2015-02-16       Impact factor: 4.679

9.  High expression of ribonucleotide reductase subunit M2 correlates with poor prognosis of hepatocellular carcinoma.

Authors:  Boin Lee; Sang Yun Ha; Dae Hyun Song; Hyun Woo Lee; Soo Youn Cho; Cheol-Keun Park
Journal:  Gut Liver       Date:  2014-11-15       Impact factor: 4.519

10.  High expression of aldo-keto reductase 1B10 is an independent predictor of favorable prognosis in patients with hepatocellular carcinoma.

Authors:  Sang Yun Ha; Dae Hyun Song; Jae Jun Lee; Hyun Woo Lee; Soo Youn Cho; Cheol-Keun Park
Journal:  Gut Liver       Date:  2014-10-07       Impact factor: 4.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.